Morgan Stanley
PBE icon

Morgan Stanley’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Morgan Stanley’s Portfolio PBE Stock Details PBE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.4M Sell
131,779
-1,524
-1% -$123K ﹤0.01% 3537
2025
Q4 		$11M Buy
133,303
+35,317
+36% +$2.73M ﹤0.01% 3533
2025
Q3 		$6.85M Sell
97,986
-93,187
-49% -$6.3M ﹤0.01% 3889
2025
Q2 		$12.3M Sell
191,173
-1,680
-0.9% -$104K ﹤0.01% 3256
2025
Q1 		$12.2M Sell
192,853
-3,187
-2% -$214K ﹤0.01% 3161
2024
Q4 		$13M Buy
196,040
+1,152
+0.6% +$79.4K ﹤0.01% 3155
2024
Q3 		$13.6M Sell
194,888
-29,831
-13% -$2.07M ﹤0.01% 3172
2024
Q2 		$14.6M Buy
224,719
+10,324
+5% +$654K ﹤0.01% 2999
2024
Q1 		$13.9M Sell
214,395
-180,633
-46% -$11.8M ﹤0.01% 3063
2023
Q4 		$26M Buy
395,028
+188,138
+91% +$10.9M ﹤0.01% 3109
2023
Q3 		$11.8M Sell
206,890
-53,275
-20% -$3.25M ﹤0.01% 2970
2023
Q2 		$15.9M Sell
260,165
-2,882
-1% -$180K ﹤0.01% 2708
2023
Q1 		$16.5M Buy
263,047
+53,095
+25% +$3.42M ﹤0.01% 2637
2022
Q4 		$13.3M Buy
209,952
+25,780
+14% +$1.64M ﹤0.01% 2770
2022
Q3 		$10.9M Sell
184,172
-1,459
-0.8% -$89.9K ﹤0.01% 2873
2022
Q2 		$10.7M Sell
185,631
-5,905
-3% -$340K ﹤0.01% 3002
2022
Q1 		$11.9M Buy
191,536
+8,959
+5% +$547K ﹤0.01% 2704
2021
Q4 		$13M Buy
182,577
+30,736
+20% +$2.23M ﹤0.01% 2632
2021
Q3 		$11.4M Sell
151,841
-1,533
-1% -$117K ﹤0.01% 2749
2021
Q2 		$11.9M Buy
153,374
+11,446
+8% +$850K ﹤0.01% 2787
2021
Q1 		$10.5M Buy
141,928
+8,039
+6% +$608K ﹤0.01% 2595
2020
Q4 		$9.39M Sell
133,889
-10,422
-7% -$660K ﹤0.01% 2572
2020
Q3 		$8.17M Buy
144,311
+3,425
+2% +$201K ﹤0.01% 2215
2020
Q2 		$8.21M Buy
140,886
+5,846
+4% +$318K ﹤0.01% 2152
2020
Q1 		$6.28M Sell
135,040
-941
-0.7% -$49.1K ﹤0.01% 2231
2019
Q4 		$7.59M Sell
135,981
-11,957
-8% -$623K ﹤0.01% 2730
2019
Q3 		$7.01M Sell
147,938
-6,589
-4% -$338K ﹤0.01% 2502
2019
Q2 		$8.27M Sell
154,527
-46,691
-23% -$2.42M ﹤0.01% 2359
2019
Q1 		$11.1M Sell
201,218
-4,620
-2% -$244K ﹤0.01% 1939
2018
Q4 		$9.69M Buy
205,838
+51,876
+34% +$2.67M ﹤0.01% 2176
2018
Q3 		$9.15M Buy
153,962
+9,391
+6% +$548K ﹤0.01% 2501
2018
Q2 		$7.91M Sell
144,571
-12,705
-8% -$646K ﹤0.01% 2640
2018
Q1 		$7.74M Buy
157,276
+6,065
+4% +$309K ﹤0.01% 2598
2017
Q4 		$7.13M Sell
151,211
-1,731
-1% -$81.1K ﹤0.01% 2701
2017
Q3 		$7.64M Buy
152,942
+5,637
+4% +$267K ﹤0.01% 2550
2017
Q2 		$6.73M Sell
147,305
-3,206
-2% -$138K ﹤0.01% 2559
2017
Q1 		$6.37M Sell
150,511
-5,672
-4% -$238K ﹤0.01% 2621
2016
Q4 		$6.06M Buy
156,183
+15,517
+11% +$627K ﹤0.01% 2789
2016
Q3 		$5.9M Buy
140,666
+21,594
+18% +$887K ﹤0.01% 2509
2016
Q2 		$4.4M Sell
119,072
-22,939
-16% -$900K ﹤0.01% 2739
2016
Q1 		$5.44M Sell
142,011
-251,870
-64% -$9.79M ﹤0.01% 2444
2015
Q4 		$19.9M Sell
393,881
-87,713
-18% -$4.33M 0.01% 1395
2015
Q3 		$22M Sell
481,594
-71,503
-13% -$4M 0.01% 1304
2015
Q2 		$32.3M Sell
553,097
-16,993
-3% -$972K 0.01% 1143
2015
Q1 		$31.4M Sell
570,090
-5,924
-1% -$320K 0.01% 1121
2014
Q4 		$28.9M Sell
576,014
-2,954
-0.5% -$145K 0.01% 1190
2014
Q3 		$26.8M Sell
578,968
-35,939
-6% -$1.62M 0.01% 1212
2014
Q2 		$26.9M Buy
614,907
+55,767
+10% +$2.26M 0.01% 1194
2014
Q1 		$23.3M Sell
559,140
-160,672
-22% -$6.87M 0.01% 1257
2013
Q4 		$26.7M Buy
719,812
+259,293
+56% +$9.3M 0.01% 1134
2013
Q3 		$16.2M Buy
460,519
+66,431
+17% +$2.2M 0.01% 1392
2013
Q2 		$11.4M Buy
+394,088
New +$11.2M 0.01% 1598

Other funds holding PBE

UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
YIA
YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

Morgan Stanley's PBE Position: Q1 2026 in Review

Morgan Stanley reduced its Invesco Biotechnology & Genome ETF (PBE) stake by 1.1% in Q1 2026, selling an estimated $123K and leaving 131,779 shares worth $10.4M. The position accounts for ﹤0.01% of the portfolio, ranked #3537.

Morgan Stanley first reported a position in PBE in Q2 2013 and has held it in 52 quarters since. The position peaked at $32.3M in Q2 2015. 100 funds tracked by Wall St. Rank hold PBE as of Q1 2026.

  • Morgan Stanley held 131,779 shares of Invesco Biotechnology & Genome ETF worth $10.4M as of Q1 2026.
  • Morgan Stanley sold 1,524 Invesco Biotechnology & Genome ETF shares in Q1 2026, an estimated $123K.
  • Invesco Biotechnology & Genome ETF made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #3537 holding.
  • Morgan Stanley first reported a position in Invesco Biotechnology & Genome ETF in Q2 2013 and has held it in 52 quarters since.
  • Morgan Stanley's Invesco Biotechnology & Genome ETF position peaked at $32.3M in Q2 2015.
  • 100 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.